Ephedrine (EC/ECA stack) vs Retatrutide
Both are used for lose fat. Here's how they compare on human evidence, mechanism, safety and availability — in plain English.
| Ephedrine (EC/ECA stack) | Retatrutide | |
|---|---|---|
| Human evidence | ★★★★☆ | ★★★★☆ |
| Legal status | Prescription, Controlled | Not Approved |
| How it works | Non-selective adrenergic agonist and norepinephrine releaser (ADRB1/2/3); centrally suppresses appetite and peripherally raises thermogenesis. Synergistic with caffeine (which blocks the negative-feedback of adenosine and… | First-in-class triple agonist — GLP1R + GIPR + glucagon receptor (GCGR). Adding glucagon-receptor agonism raises energy expenditure and hepatic fat oxidation on top of the twin appetite pathways. |
| In plain English | Flips your "fight or flight" system on a little, which curbs hunger and burns more calories. Effective but raises heart rate and blood pressure — restricted for that reason. | Three metabolic switches in one molecule — two cut hunger, the third turns up calorie-burning. In the Phase 3 TRIUMPH-4 trial (Dec 2025) it produced 28.7% weight loss at 68 weeks — the largest ever for a drug. Not yet approved. |
| Bottom line | Genuinely works; cardiovascular risk got it pulled from most shelves. | The likely next leader once approved. Source: Lilly TRIUMPH-4 release. |
| Availability | Controlled substance | Not widely approved |
Which is better for lose fat?
Both carry a comparable human-evidence rating (★★★★☆). Choose on mechanism fit, side-effects, availability and cost rather than evidence strength alone — they work through different mechanisms.
Full breakdowns: Ephedrine (EC/ECA stack) · Retatrutide.
Common questions
Is Ephedrine (EC/ECA stack) or Retatrutide better for lose fat?
Both carry a comparable human-evidence rating (★★★★☆). Choose on mechanism fit, side-effects, availability and cost rather than evidence strength alone — they work through different mechanisms.
What's the difference between Ephedrine (EC/ECA stack) and Retatrutide?
Ephedrine (EC/ECA stack): Genuinely works; cardiovascular risk got it pulled from most shelves. — Retatrutide: The likely next leader once approved. Source: Lilly TRIUMPH-4 release.